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What Is the Optimal Approach to Major ABO-Incompatible
Allogeneic Stem Cell Transplantation?
Dawn Sheppard*, Lothar B. Huebsch, Christopher Bredeson
Department of Haematology, The Ottawa Hospital, Ottawa, Ontario, CanadaIn a recent issue of BBMT, Booth et al. [1] reviewed ap-
proaches to the management of ABO-incompatible allogeneic
hematopoietic progenitor cell (HPC) transplantation (HCT).
Major ABO incompatibility may be addressed by
RBC depletion of the HPC product or reduction of recipient
isohemagglutinins by plasma exchange, column immu-
noadsorption, donor-type secretor plasma, or in vivo immu-
noadsorption using donor RBCs [2-6]. As the authors state in
their review, there is no consensus as to the best method of
managing ABO-incompatible HCT [2], and there have been no
direct comparisons of available methods.
In our opinion, the conclusion that RBC depletion is
the optimal approach to managing major ABO mismatch
is unduly restrictive. We recently reported the results of a
10-year retrospective analysis of recipient isohemagglutinin
reduction by plasma exchange for major ABO-incompatible
bone marrow grafts [7]. In our experience, engraftment
times, transfusion requirements, incidence and severity of
graft-versus-host disease, and 100-day treatment-related
mortality did not differ between the patients with a major
ABO donor mismatch and those with an ABO-compatible
donor. No hemolytic transfusion reactions were observed
during product infusion.
As Booth et al. point out, RBC depletion of the HPC
product can reduce the total nucleated cell count [8]. This is
of particular importance if the HPC content is low or if
additional cells are not readily available, as with cord blood
units or volunteer unrelated donor grafts. In addition,
because unrelated donor HPC products can come from any-
where in the world, and prolonged intervals between
collection and infusion into the recipient are associated with
decreased likelihood of engraftment and increased mortality
[9], further product manipulation in these circumstances is
undesirable. As such, Table 4 in their review, under “HPC
acquisition and potential manipulation,” the ﬁrst bullet,1083-8791/$ e see front matter  2013 American Society for Blood and Marrow“major mismatch” should include RBC depletion or plasma
exchange.
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Garrett S. Booth*, Eric A. Gehrie, Bipin N. Savani
1Vanderbilt University Medical Center, Department of Pathology, Microbiology and Immunology, Nashville, Tennessee
2 Yale University, Department of Laboratory Medicine, New Haven, Connecticut
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Cancer Center, Vanderbilt University Medical Center, Nashville, TennesseeIn response to our recent review article [1], Sheppard et al.
[2] note that plasmapheresis can be used to diminish recipient
A and B antibodies before infusion of a major ABO-incompatible hematopoietic progenitor cell graft. Although
recipient plasma exchangemay lower the titer of incompatible
antibody, antibody titering is a laboratory technique shown toTransplantation.
D. Sheppard et al. / Biol Blood Marrow Transplant 19 (2013) 1760e1761 1761be difﬁcult to standardize across institutions [3,4]. Therefore,
we anticipate that it may be difﬁcult to determine whether a
concentration of incompatible antibody can be universally
considered to be protective against a hemolytic reaction.
Furthermore, we note that some patients in the study by
Sheppard et al. had nominal (1 titer step or less) reductions
in their anti-A or anti-B titers after plasma exchange. In
addition, there were no hemolytic reactions reported even
though numerous subjects did not reduce their anti-A or
anti-B titers to the goal level. Taken together, these consid-
erations raise the possibility that a factor besides recipient
anti-A or anti-B antibody concentration determines pro-
pensity toward hemolysis in the setting of ABO-incompatible
stem cell transplantation (SCT). In addition, there does not
seem to be an association between anti-A or anti-B antibody
concentration and the development of pure red cell aplasia
in ABO-incompatible SCT [5].
Our suggested approach is to infuse major ABO-
incompatible SCTs at a slow rate and monitor for signs of
hemolysis. Additional hematopoietic progenitor cell product
modiﬁcation can be undertaken, including red cell sedi-
mentation if clinically indicated. If no hemolysis occurs, then
the transplant can continue in an unmodiﬁed manner.ACKNOWLEDGMENTS
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